Adverse reaction characteristics of five COVID-19 vaccines across different technology platforms: a pooled analysis of nine clinical trials

Adverse reaction characteristics of five COVID-19 vaccines across different technology platforms: a pooled analysis of nine clinical trials

Background Evidence regarding the comparative safety of different COVID-19 vaccines remains limited. This study aims to characterize and compare the safety profiles of five COVID-19 vaccines in terms of adverse reactions after immunization.Research design and methods We conducted a retrospective ana...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yue Liu, Qian Liu, Lai-Run Jin, Wei-Wei Han, Ming-Wei Wei, Si-Yue Jia, Feng-Cai Zhu, Jing-Xin Li
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Series:	Expert Review of Vaccines
Subjects:	Adverse reactions aerosolized Ad5 vectored vaccine COVID-19 vaccines inactivated vaccine intramuscular Ad5 vectored vaccine intranasal influenza-vectored vaccine
Online Access:	https://www.tandfonline.com/doi/10.1080/14760584.2025.2502031
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Protection Against Rabies Induced by the Non-Replicative Viral Vectors MVA and Ad5 Expressing Rabies Glycoprotein
by: Debora Patricia Garanzini, et al.
Published: (2025-03-01)

Safety comparison of mRNA, viral vector, and inactivated Covid-19 vaccines: incidence of adverse events following primary and booster doses among medical professionals in Malaysia
by: Rekha Prabhu, et al.
Published: (2025-07-01)

Antibody dynamics for heterologous boosters with aerosolized Ad5-nCoV following inactivated COVID-19 vaccines
by: Canjie Chen, et al.
Published: (2024-12-01)

Analysis of Promising Approaches to COVID-19 Vaccine Development
by: G. G. Onishchenko, et al.
Published: (2020-12-01)

Chimpanzee adenoviral vector prime-boost regimen elicits potent immune responses against Ebola virus in mice and rhesus macaques
by: Xi Yang, et al.
Published: (2019-01-01)

The past, present and future of duck plague virus vaccines
by: Linjiang Yang, et al.
Published: (2025-03-01)

Adenoviral-vectored vaccine against Bordetella pertussis fimbrial antigen induces partial protection in a mouse model
by: Alexa Dierig, et al.
Published: (2025-06-01)

Research of recombinant influenza A virus as a vector for Mycoplasma pneumoniae P1a and P30a
by: Liang Yu, et al.
Published: (2024-09-01)

The current state of H5N1 vaccines and the use of the ferret model for influenza therapeutic and prophylactic development
by: David Banner, et al.
Published: (2012-05-01)

Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years with or without previous influenza vaccination histories
by: Feng Wen, et al.
Published: (2025-12-01)

Real-world effectiveness of live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) in children from 2003 to 2023: a systematic literature review and network meta-analysis
by: Anke L. Stuurman, et al.
Published: (2025-12-01)

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trialResearch in context
by: Gabriela Tapia-Calle, et al.
Published: (2025-01-01)

Developing the next-generation of adenoviral vector vaccines
by: Alexander T. Sampson, et al.
Published: (2025-12-01)

A prospective, randomized, parallel, active controlled, phase III Indian study of immunogenicity and safety of two inactivated influenza vaccines - Vaxiflu-4 and Fluarix tetra in children aged 6 months to 35 months
by: Kairav Kothari, et al.
Published: (2024-12-01)

Accelerating vaccine development: Plug-and-play platforms for emerging infectious diseases
by: Kairui Yang
Published: (2025-08-01)

Harnessing live vectors for cancer vaccines: Advancing therapeutic immunotherapy
by: Chinmay T. Jani, et al.
Published: (2025-12-01)

Assessing the impact of a potential canine vaccine for the control of Chagas disease: a mathematical modeling study
by: Edem Fiatsonu, et al.
Published: (2024-10-01)

Linked empirical studies reveal the cumulative impact of acquired tick resistance across the tick life cycleMendeley Data
by: J.P. Owen, et al.
Published: (2025-05-01)

Results of a clinical study of the influenza tetravalent inactivated subunit adjuvant vaccine Grippol Quadrivalent in children aged 6 months to 5 years (inclusive)
by: Viktor V. Romanenko, et al.
Published: (2024-07-01)

Comparative Analysis of Approaches to Assess the Quality of Inactivated Influenza Vaccines: Regulatory Requirements in the Russian Federation and European Union
by: L. M. Khantimirova, et al.
Published: (2021-01-01)

The Study in Animal Models of Local Action, Acute and Chronic Toxicity of Inactivated Influenza Vaccine Ultriks in Syringe
by: O. G. Kurskaya, et al.
Published: (2015-06-01)

Genetic adjuvants: A paradigm shift in vaccine development and immune modulation
by: Karina Spunde, et al.
Published: (2025-06-01)

A Study on Determining the Level of Knowledge about Influenza, Pneumococcal, Herpes Zoster, and Tetanus Vaccines among the Vaccines Recommended by the World Health Organization and the Level of Vaccination in Individuals Sixty-Five Years Old and Over
by: Alpay Medetalibeyoğlu, et al.
Published: (2020-10-01)

Commentary: Inactivated rabies virus vectored MERS-Coronavirus vaccine induces protective immunity in mice, camels, and alpacas
by: Shengnan Yang, et al.
Published: (2025-03-01)

Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization
by: William R. Lykins, et al.
Published: (2024-12-01)

Safety and immunogenicity of GamEvac-Combi, a heterologous rVSV- and rAd5-vectored Ebola vaccine: a randomized controlled multicenter clinical trial in the Republic of Guinea and Russia
by: Denis Y. Logunov, et al.
Published: (2025-03-01)

Early and Late Influenza Vaccine Effectiveness in South Korea During the 2023–2024 Season
by: Yu Jung Choi, et al.
Published: (2025-02-01)

Nanotechnology-driven advances in intranasal vaccine delivery systems against infectious diseases
by: Zhihan Zhang, et al.
Published: (2025-05-01)

Efficacy and Safety of Cholera Vaccines
by: A. A. Goryaev, et al.
Published: (2018-03-01)

Enhanced passive safety surveillance of standard-dose and high-dose influenza vaccines in Finland and Germany 2023–24 season
by: Marina Amaral de Avila Machado, et al.
Published: (2025-12-01)

Modern Ideas about Vaccination of Patients with Rheumatic Diseases: the View of ACR Experts
by: B. S. Belov, et al.
Published: (2023-10-01)

Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2
by: Muralimanohara S. T. Murala, et al.
Published: (2025-04-01)

ADVERSE EVENTS FOLLOWING PENTAVALENT VACCINE ADMINISTRATION: A DESCRIPTIVE STUDY IN THE INDIAN CONTEXT
by: Roop Sharma, et al.
Published: (2025-05-01)

Relationship between parental vaccine literacy and their willingness to vaccinate children against influenza in china
by: Zhuoran Huang, et al.
Published: (2025-12-01)

Vaccination in Chronic Obstructive Pulmonary Disease
by: Wang-Chun Kwok, et al.
Published: (2025-02-01)

Development and Evaluation of a Candidate Inactivated Vaccine Against Bluetongue Virus Serotype 4 (BTV4)
by: Ljubisa Veljovic, et al.
Published: (2024-11-01)

Influenza, pneumococcal, and COVID-19 vaccination coverage and hesitancy in adults with psychiatric disorders
by: Vasfiye Demir Pervane, et al.
Published: (2025-04-01)

The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018–2024
by: Yihao Li, et al.
Published: (2025-12-01)

Attitudes, Beliefs, and Self-Reported Rates of Influenza and COVID-19 Vaccinations in the Canadian 2023–2024 National Influenza and Respiratory Viruses Survey
by: Samir Sinha, et al.
Published: (2024-10-01)

Vaccinia Virus Vector Bivalent Norovirus Vaccine
by: Yunbo Bai, et al.
Published: (2025-02-01)